home-bg-image.jpg

Latest news

Blue-Earth logo 900400.jpg 5 January 2021

Blue Earth Diagnostics Acquires Exclusive, Worldwide Rights to Therapeutic Applications of Scintomics’ Radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) Technology for Prostate Cancer

Blue Earth Diagnostics has exercised an option to acquire exclusive, worldwide rights to therapeutic applications of novel radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) technology in prostate cancer

Read more
Header_news_point_thumbnail.jpg 10 March 2020

POINT Biopharma and SCINTOMICS Announce License Agreement

POINT Biopharma Inc. today announced that it has entered into an agreement with SCINTOMICS GmbH for the exclusive use and development of a family of more than seventy patented next generation PSMA radioligands for targeted radiotherapy of prostate cancer. Under the terms of the agreement, POINT has acquired both North American and broad international rights to the compounds.

Read more
PentixaPharm thumbnail news.jpg 6 February 2020

PENTIXAPHARM Secures € 15 Million Series A Financing to Develop CXCR4-Targeted Theranostics

Feburary 6th 2020, WÜRZBURG, Germany--PentixaPharm announced today to have secured € 15 million in a series A financing round led by ELSA Eckert Life Science Accelerator.

Read more
technische-universitat-munchen-tum-logo.png 3 July 2019

Scintomics gewinnt TUM Presidential Entrepreneurship Award

Scintomics hat den diesjährigen TUM Presidential Entrepreneurship Award gewonnen. Das Unternehmen entwickelt radiopharmazeutische Technologien zur Krebsdiagnose.

Read more
PentixaPharm thumbnail news.jpg 15 May 2019

Scintomics and 1717 Life Science Ventures Team up

Scintomics and 1717 LSV to collaborate in the development of novel cancer diagnostics and treatment.

Read more
Blue-Earth logo 900400.jpg 2 May 2018

Blue Earth Diagnostics Expands Oncology Portfolio with Exclusive, Worldwide Licensing of Investigational Radiohybrid PSMA-targeted Agents for Prostate Cancer from Scintomics

Blue Earth Diagnostics has acquired the exclusive worldwide rights to a broad family of Prostate Specific Membrane Antigen (PSMA)-targeted radiohybrid (“rh”) agents for cancer imaging, together with an exclusive option to explore therapeutic applications.

Read more
  • 1